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Abstract
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a rare and
lethal developmental disorder of the lung defined by a constellation of characteristic
histopathological features. Non-pulmonary anomalies involving organs of gastrointestinal,
cardiovascular, and genitourinary systems have been identified in approximately 80% of patients
with ACD/MPV. We have collected DNA and pathological samples from more than 90 infants
with ACD/MPV and their family members. Since the publication of our initial report of four point
mutations and ten deletions, we have identified an additional thirty eight novel nonsynonymous
mutations of FOXF1 (nine nonsense, seven frameshift, one inframe deletion, twenty missense, and
one no stop). This report represents an up to date list of all known FOXF1 mutations to the best of
our knowledge. Majority of the cases are sporadic whereas four familial cases with three showing
maternal inheritance, consistent with paternal imprinting of the gene. Twenty five mutations
(60%) are located within the putative DNA binding domain, indicating its plausible role in gene
regulation. Five mutations map to the second exon. We identified two additional genic and eight
genomic deletions upstream to FOXF1. These results corroborate and extend our previous
observations and further establish involvement of FOXF1 in ACD/MPV and lung organogenesis.
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Background
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV; MIM#
265380) is a rare lethal developmental disorder of the lung and its vasculature [Bishop, et
al., 2011]. Affected patients typically develop severe respiratory distress and pulmonary
hypertension a few hours after birth, although rare late presentations have also been reported
[Ahmed, et al., 2008; Licht, et al., 2004]. Supportive treatment with supplemental oxygen,
inhaled nitric oxide, extracorporeal membrane oxygenation (ECMO) and, more recently,
sildenafil provide only temporary improvement [Al-Hathlol, et al., 2000; Kitayama, et al.,
1997; Plat, et al., 2007]. There is no cure for the disease and affected infants usually die
within the first month of their life. The diagnosis of ACD/MPV has been based on the
presence of a constellation of histologic abnormalities on lung biopsies or at autopsy and
include malposition (misalignment) of pulmonary veins adjacent to small pulmonary
arteries, medial thickening of the smooth muscle walls of small pulmonary arteries, deficient
pulmonary lobular development, and severe paucity of normally positioned alveolar wall
capillaries (Fig. 1) [Wagenvoort, 1986]. About a third of the patients with ACD/MPV also
have pulmonary lymphangiectasis [Langston, 1991] and most (approximately 80%) have
anomalies of other organs, particularly of the cardiovascular, gastrointestinal, and
genitourinary systems [Sen, et al., 2004]. The vast majority of ACD/MPV cases are sporadic
although a few familial cases have been reported [Boggs, et al., 1994; Gutierrez, et al., 2000;
Sen, et al., 2012].
In 2009, we reported four unique heterozygous inactivating point mutations (one nonsense,
one no stop, and two frameshift; patients 38–41 in Table 1), and 10 microdeletions involving
FOXF1 and its upstream interval in the 16q24 (Fig. 2, D1–D6, D8–D10) region, in about
40% of patients with ACD/MPV analyzed [Stankiewicz, et al., 2009]. Since the publication
of that report, we have accumulated material from 53 additional cases of histologically
diagnosed ACD/MPV and five cases identified genetically. Recently, we have shown that
FOXF1 is incompletely paternally imprinted in humans [Sen, et al., 2012; Szafranski, et al.,
2013].
We now report 34 novel de novo and four familial mutations of which three are maternally
inherited, in unrelated patients with ACD/MPV that imply a role for FOXF1 DNA-binding
domain (DBD) (Table 1). This report represents an up to date list of all known FOXF1
mutations to the best of our knowledge. Our data further substantiate the notion that
mutations in FOXF1 lead to manifestation of ACD/MPV and that this transcription factor is
involved in the development of the pulmonary, cardiovascular, gastrointestinal, and
genitourinary systems. Three maternally inherited cases are consistent with the finding that
FOXF1 is paternally imprinted [Sen, et al., 2012; Szafranski, et al., 2013].
Variants
The exact location and other pertinent information for each mutation are detailed in Table 1
and Fig. 3. Patient 7 has two mutations of unknown phase. Twenty nine of the newly
identified mutations (patients 1, 2, 5, 7a & b, 8, 9, 11, 12, 15, 16, 18, 20, 21, and 23 – 37) are
substitution point mutations (missense, nonsense, and no stop), one generates a premature
stop codon at the site of the deletion (patient 3), one is an in frame deletion (patient 10), one
is indel (patient 21) and four (patients 6, 13, 14, and 22) are small deletions, and two
(patients 4 and 17) are insertions, resulting in a shift in the FOXF1 reading frame. These are
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all unique mutations and only patient 37 [Sen, et al., 2012] and 38–41 [Stankiewicz, et al.,
2009] have been previously reported. Two groups of mutations affect the same codon but
involve different nucleotides; thus resulting in different amino acids (Table 1): patients
25,34 and 35 (c.254T>C, p.Phe85Ser, c.253T>A;p.Phe85Ile & c.253T>C, p.Phe85Leu); and
a pair of one new (patient 11) and a previously reported (patient 37) mutation change the
stop codon while involving separate nucleotides, and extend the protein by 73 amino acids
(c.1139G>C, p.*380Ser ext*73& c.11138T>C, p.*380Argext*73).
The identified mutations are not reported in the dbSNP and are not cited in the Exome
Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL: http://
evs.gs.washington.edu/EVS/), that covers more than 10,000 alleles. There are three known
SNPs (rs61740819, rs61753347, and rs8061302) [Common SNPs (135)] in the first exon of
FOXF1 outside the DBD. SNPs rs61740819 and rs61753347 map within the cell specific
activation domain of FOXF1 (Mahlapuu, et al., 1998; Pierrou, et al., 1994) [Mahlapuu, et
al., 1998; Pierrou, et al., 1994], and are both synonymous. The third one, rs8061302,
changes a proline to threonine at position 299 (Fig. 3B). Although this proline is conserved
among other FOXF1 orthologs, we believe this SNP is neutral because it is present outside
the DBD of the protein. The sources of these SNPs are unknown. The reference sequence
used in this study is NM_001451.2.
Figure 3B shows the locations and types of all identified mutations. In patient 1 and 31, the
nonsynonymous missense mutation is predicted to lead to a proline to serine or glutamine
change, respectively, at the 49th position that is within the DBD of FOXF1 and is conserved
in members of the forkhead family of proteins (Fig. 3C) [Pierrou, et al., 1994]. A proline
residue is known to create a kink in protein structure [Langelaan, et al., 2010; Vanhoof, et
al., 1995]. Therefore, these changes in the primary structure of the protein is likely to
produce a substantial alteration in its three dimensional structure, especially in the forkhead
domain, thus affecting its DNA binding function. Missense mutations in patients 8
(p.Arg86Trp), 9 (p.Ser101Leu), 12 (p.Tyr53Cys), 15 (p.Val96Met), 16 (p.Ile74Asn), 20
(p.Ser52Phe), 21 (p.Gly91Glu), 24 (p.Arg97His), 25 (p.Phe85Ser), 26 (p.Gly119Asp), 27
(p.Gly91Val), 32 (p.Pro126Leu), 33 (p.Phe126Leu), 34 (p.Phe85Ile), 35 (p.Phe85Leu), 36
(p.His98Gln), 37 (p.Arg139Leu) also map within the DBD of the protein. Arginine and
serine residues have also been shown to be involved in DNA binding [Kirchler, et al., 2010;
Wache, et al., 2005; Wei, et al., 2003]. All of the 15 amino acids within the DBD of FOXF1
that are altered due to missense mutations are conserved in vertebrates and other members of
the forkhead family (Fig 3C). These missense mutations are important since they provide
information regarding the function of FOXF1 as a transcription factor with DNA binding
ability.
Patients 2 (p.Ser30*), 5 (p.Ser64*), 7a (p.Gln79*), 18 (p.W92*), 23 (p.Ser180*), 28
(p.Glu104*), 29 (p.W270*), and 30 (p.Q288*) have nonsense mutations introducing
premature stop codons. The mutations in patients 5, 7, and 18 also map to the DBD. In
patient 7, an additional variant of unknown significance was identified in the second exon
and is predicted to lead to p.Arg330Trp (Table 1) change.
Deletion of eight bases in patient 3 introduces a stop codon at the point of rearrangement.
Patients 6 (p.Ala231Argfs*61), 13 (p.Tyr313Ilefs*66), 14 (p. Leu300Argfs*79), 17
(p.His238Alafs*57), and 19 (p.Arg341Glnfs*70) have deletions of various numbers of bases
thereby altering the reading frame and introducing premature stop codons. Patient 10
(p.Leu113_G119del) has an inframe deletion of seven amino acids resulting in a shorter
polypeptide without altering the reading frame. Patient 21 has a deletion and reciprocal
insertion of two bases, thereby maintaining the reading frame with a p.Gly91Glu missense
mutation (Table 1). All except one (patient 19) of these deletion mutations are in the first
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exon of the FOXF1 with the mutation in patients six and 10 being present within the DBD of
the protein. Interestingly, in patient 10, the deletion is flanked by a direct repeat sequence
AAGGGCC, which might have provided microhomology for the deletion [Boone, et al.,
2011; Hastings, et al., 2009].
The insertion of five nucleotides (CCTGT) after 903 bases from the first codon in patient 4
results in no change in the size of the predicted polypeptide although only first 301 amino
acids remain unchanged. The mutation in patient 19 also represents an out-of-frame
insertion of a single base in the first exon, leading to an extension of 30 amino acids in the
protein.
The three familial cases (patients 35, 36 and 37) show maternal inheritance of the mutated
allele. Investigation of one of the families (patient 37) showed that the missense mutation in
the children arose de novo on the paternal allele of the mother [Sen, et al., 2012]. Patients
34.1 and 34.2 have the same mutation although none of their parents have it. This situation
could be explained as an example of germline mosaicism most probably in the mother since
the gene is paternally imprinted. However, in patient 36 we could not determine whether the
mutation is inherited or de novo on the paternal allele in the mother due to lack of DNA
samples from her parents. The familial cases represent almost 10% of the total mutations
presented herein. It is likely that other inactivating mutations in FOXF1 might be present in
the general population but they do not manifest ACD/MPV and thus remain undetected as
they are most likely located on the paternal chromosome 16 of unaffected carriers.
Fifteen nonsense and frameshift mutations of the 42 new and previously reported mutations
presented here, map to the first exon of the FOXF1 gene, resulting in premature stop codons.
Thus, the aberrant mRNA is likely to be destroyed by the nonsense mediated decay (NMD)
surveillance mechanism [Bhuvanagiri, et al., 2010; Nicholson, et al., 2010] and, leading to
FOXF1 haploinsufficiency. The frameshift mutations in patients 4, 13, 14, and 19 change
the predicted amino acid sequence from their respective point of mutation and while
mutation in patient 19 extends the predicted polypeptide sequence, mutations in patients 4,
13 and 14, result in predicted polypeptides that are equal in size with the wild type protein.
The missense mutations p.Arg330Trp in patient 7, p.*380Serext*73 in patient 11, the no
stop mutation extending the protein with 73 amino acids, and an insertion of a single base c.
1021_1022insA in patient 19, are predicted to escape the NMD. We reported another no
stop mutation previously [Stankiewicz, et al., 2009].
In addition to the previously reported 12 microdeletions involving FOXF1 and its upstream
region [Garabedian et al., 2012; Handrigan et al., 2013; Stankiewicz, et al., 2009; Yu, et al.,
2010; Zufferey, et al., 2011], we have recently identified ten novel de novo deletions: two
involving FOXF1 and eight mapping upstream to FOXF1(Fig. 2). Interestingly, among
deletions for which parental origin could be determined (eight upstream and seven others
harboring FOXF1) each arose de novo on the maternal chromosome, consistent with the fact
that FOXF1 is paternally imprinted. The deletions enabled identification of a distant cis-
regulatory region (Fig. 2; SDR: Smallest Deleted Overlapping Region) mapping at 250 kb
upstream to FOXF1 that harbors lncRNA genes, a differentially methylated CpG island that
binds GLI2 depending on its methylation status, and physically interacts with and up-
regulates the FOXF1 promoter [Szafranski, et al., 2013].
The data presented here corroborate our earlier results of involvement of FOXF1 in ACD/
MPV where we had identified point mutations or deletions involving FOXF1 in about 40%
of 46 patients studied. We have since identified mutations in FOXF1 in 70% (37/53) of 53
additional patients and also found 10 more deletions. This further proves that FOXF1
haploinsufficiency is the major cause of ACD/MPV and its essential role in the development
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of the lungs and other organs. With approximately 60% (25/42) of the mutations located in
the DBD, our data also indicate that this domain of the protein plays an important role in
mediating its function as a transcription factor. All mutations are predicted to be deleterious
by bioinformatics analysis (Table 1) [Adzhubei, et al., 2010; Kumar, et al., 2009; Mathe, et
al., 2006].
Databases
The mutations have been deposited in the LOVD database (www.lovd.nl/FOXF1).
Consortium
FOXF1 is one of the research interests of a few laboratories (Dr. Vladimir Kalinichenko,
Cincinnati Children’s Hospital, Ohio, USA and Dr. Charles Shaw-Smith, Peninsula College
of Medicine and Dentistry, Exeter, UK). However, we are the only group that is interested in
the genetic abnormalities of FOXF1, related to ACD/MPV, and there are currently no
consortia that specifically study this particular entity, although the Childhood Interstitial
Lung Disease Research Network has considered inclusion of patients with ACD/MPV in an
as yet not activated patient registry. Our group has benefited from the activities of the
“ACD-Association (ACDA)” (http://www.acd-association.com), an organization formed in
1996 to support families affected by ACD/MPV. This organization has been a source of
information and support for parents of ACD/MPV patients. Recently, “The Breath of Life
Project” (http://breathoflifeproject.com/), has provided information about ACD/MPV to
physicians and other health professionals as part of a CDC (Centers for Disease Control and
Prevention, Atlanta, GA) funded awareness project.
Biological Relevance
The FOXF1 protein is a dosage-sensitive transcription factor that binds to the promoter
regions of other genes involved in organogenesis [Madison, et al., 2009; Mahlapuu, et al.,
2001; Shaw-Smith, 2010]. It contains a forkhead (DNA binding) domain between amino
acids 44–148 [Pierrou, et al., 1994] and two more activation domains, one of which,
between amino acids 135 and 260 (encoded by the first exon), has been shown to
specifically activate genes in the lung. The last 28 amino acids at the C terminus of the
protein constitute the second activation domain that is involved in general gene expression
in all cell types (Fig. 2) [Mahlapuu, et al., 1998]. Moreover, it is known that FOXF1 binds as
a monomer [Pierrou, et al., 1994]. Further, FOXF1 has recently been shown to be
incompletely paternally imprinted in human [Sen, et al., 2012; Szafranski, et al., 2013]. The
members of the Fox family of transcription factors (Forkhead box) are a group of ancient
proteins that originated in unicellular eukaryotes. Through evolution, they have multiplied to
several copies and currently there are approximately 40 such proteins in mammals
[Hannenhalli and Kaestner, 2009]. They play important roles in functions as diverse as cell
cycle controls, organ development, and language disorders. Some of the Fox proteins have
been implicated in various types of cancer [Katoh et al., 2013].
Homozygous Foxf1−/− mice die by embryonic day 8.5 because of defects in the
development of extra-embryonic mesoderm [Kalinichenko, et al., 2001a; Mahlapuu, et al.,
2001]. Heterozygous knockout mice (Foxf1+/−) showed phenotypes similar to ACD/MPV.
Although there is no misalignment of veins, reduction in the number of alveolar capillaries
and lymphangiectasis are observed both in mice and humans. Interestingly, half of the
newborn mice (Foxf1+/−) died of severe defects in alveolarization, vasculogenesis, and
pulmonary hemorrhage [Kalinichenko, et al., 2001b]. Other defects such as fusion of lung
lobes, abnormal gall bladder, and esophageal atresia were also observed [Kalinichenko, et
al., 2001a; Kalinichenko, et al., 2001b; Mahlapuu, et al., 2001]. The remaining Foxf1+/−
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mice showed normal lung morphology that was interpreted as “compensation” for the defect
[Kalinichenko, et al., 2001b].
Transcription factors bind to specific DNA sequences and thereby affecting gene expression.
This is done through a DBD of which there are many different types. Members of the
forkhead family have a winged helix-turn-helix domain that is known as the “forkhead
domain” that functions as the DBD in them. It is interesting to note that 60% of all the
mutations reported here are located within the DBD of FOXF1. Further, 88% of the
mutations in the first exon and 95% of all missense mutations are clustered in the DBD of
the protein. This clearly suggests that this domain plays a crucial role in the proper
functioning of this important transcription factor since changes in this domain of the FOXF1
protein may affect its DNA binding properties resulting in ACD/MPV. Specific in vitro
DNA binding experiments with the modified proteins mimicking the missense mutations are
required to conclusively determine their role in the DBD of FOXF1.
Foxf1 expression in mice is thought to be regulated by Bmp4 [Astorga and Carlsson, 2007]
Gli2 [Astorga and Carlsson, 2007; Tseng, et al., 2004], and by Pten [Tiozzo, et al., 2012]. A
reduced expression of Vegfa, Vegfr2, Bmp-4, Tbx, Lklf, Fgf-10, Gli3, and Notch-2 has been
observed in Foxf1−/− mice [Hellqvist, et al., 1996; Kalinichenko, et al., 2004; Kalinichenko,
et al., 2001b; Lim, et al., 2002; Mahlapuu, et al., 2001].
Clinical Relevance
Patients with ACD/MPV were recruited after having signed consent approved by the IRB of
Baylor College of Medicine (BCM). ACD/MPV is a rare and lethal developmental disorder
presenting as respiratory distress and persistent pulmonary hypertension of the newborn
[Abazov, et al., 2003; Bishop et al., 2011]. Initially, patients with ACD/MPV typically
present with a clinical course consistent with persistent pulmonary hypertension without
ready explanation. Further, approximately 80% of patients with ACD/MPV also have
defects of non-pulmonary organ system [Sen, et al., 2004]. In addition, approximately 65%
of the ACD/MPV families reported a history of miscarriages (data unpublished). As FOXF1
is also expressed in the placenta [Hellqvist, et al., 1996; Shaut, et al., 2008], this finding
needs to be further investigated. A clinical summary of the presented cases is outlined in
Table 2.
We would like to emphasize that although ACD/MPV is a rare diffuse disorder of the
neonatal lung, it is very likely that the diagnosis is missed in a significant number of patients
due to lack of biopsies and autopsies. Further, we advocate that FOXF1 testing be done in
patients with refractory pulmonary hypertension. This will result in a much larger cohort.
Two retrospective studies have confirmed this notion [Eulmesekian, et al., 2005; Tibballs
and Chow, 2002].
Diagnostic Relevance
About 200 cases of ACD/MPV have been reported in the literature [Sen, et al., 2010]. As
physicians, pathologists, genetic counselors and care givers are becoming more cognizant
with the disorder; more diagnoses are being made through histological examination of lung
biopsies. A CLIA (Clinical Laboratory Improvement Amendment) certified service for the
detection of mutation and deletion in suspected prenatal and postnatal cases is now available
through the Medical Genetics Laboratories at the BCM, Houston, TX (https://
www.bcm.edu/geneticlabs/). We continue to offer the analyses for genetic alterations of
FOXF1 including mutation and deletion on a research basis. Results of such studies will
help to provide better genetic counseling and estimates of recurrence risks to facilitate
parents of ACD/MPV patients planning for future pregnancies. Very few lung transplants
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have been performed successfully. However, all of these patients have atypical late
presentation of ACD/MPV (personal communication, Jennifer Wambach, Washington
University, St. Louis, MO).
Future Prospects
We continue to investigate the molecular bases of lung development with a particular
reference to FOXF1 and interacting genes. As a transcription factor, FOXF1 expectedly
might regulate the expression of a number of downstream genes that are involved in lung
and pulmonary vascular development. The early identification of affected infants by analysis
for abnormalities of the FOXF1 gene may aid management decisions for these infants,
conserving health care resources.
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Figure 1.
Sections of formalin fixed paraffin embedded lung tissue obtained either at autopsy (Cases 1
and 2) or diagnostic lung biopsy (Case 7) are examined stained with hematoxylin and eosin
for the constellation of changes seen in ACD/MPV. These changes are often confirmed with
a variety of additional stains including Movat pentachrome, trichrome and elastic stains and
immunostains for pulmonary epithelium (CK7), the microvasculature (CD31) and vascular
smooth muscle (Smooth Muscle Actin) (not shown). These changes include increased
medial smooth muscle in small pulmonary arteries (black arrows), malposition of pulmonary
veins (white arrows) adjacent to small pulmonary arteries in their normal parabronchiolar
location (B identified bronchioles), and lobular underdevelopment seen in all panels. Other
changes include paucity of alveolar capillaries and abnormal capillary size and location,
seen in panels “a” and “b” as centrally located thin-walled dilated and congested alveolar
wall vessels. Images are from Case 1 (a), Case 2 (b), and Case 7 (c); all H&E stain.
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Figure 2.
Genomic and genic deletions identified in the 16q24.1 region in patients with ACD/MPV.
Patients D1–D6 and D8–D10 have been reported in Stankiewicz et al 2009 and the
remainder except 94.3 and 104.3 have been reported in Szafranski et al (2013). Note that
many of the deletions are flanked by Alu repetitive segments. SDR represents the smallest
deletion overlap defining the cis-regulatory region mapping 250 kb upstream of FOXF1
(Szafranski et al 2012). The numbers with decimals refer to patients with ACD/MPV in our
cohort.
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Figure 3.
A: Schematic representation of FOXF1 at 16q24.1. The upper segment depicts the genomic
arrangement of FOXF1 with two exons in the gene shown by open boxes. The non-coding
part of the gene is shown in shaded boxes. The numbers underneath show the beginning and
end of the coding sequences and the exon intron junctions. The lower segment depicts the
protein with the relative location of the DNA binding “Forkhead box” domain (DBD) and,
the Cell-type specific activation domain in exon 1 and the general activation domain in exon
2. The numbers underneath indicate the position of amino acids for the domains.
B: Positional representation of all reported and novel mutations in FOXF1. The green solid
lines and green shaded boxes represent the first exon while the red solid line and the red
shaded box represent the second exon. The first exon contains the DNA binding domain and
the cell-type specific activation domain and the second exon contains the general activation
domain. The locations of the mutations are shown with arrows. Golden arrows indicate
nonsense mutations, purple, blue and green arrows indicate missense mutations, frameshift
and indel mutations and no-stop mutations, respectively. The details of the mutations are
shown above respective arrows. The black arrow indicates the nonsynonymous SNP.
C: Evolutionary conservation of the amino acid sequence of the DNA binding domain of
FOXF1 among vertebrates and conservation of the mutated amino acids within other
forkhead family proteins. The identical amino acids are shown in blue while conservative
changes are shown in burgundy and non-conservative changes shown in green. Only
missense mutations are shown. The resulting amino acids after mutations are shown between
the two panels. Although two of the missense mutations in unrelated patients involve the
same amino acids the resulting changed amino acids are different in each case. The resulting
amino acids are shown one above the other.
Sen et al. Page 13
Hum Mutat. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sen et al. Page 14
Ta
bl
e 
1
Li
st 
of
 m
ut
at
io
ns
 in
f F
OX
F1
 
co
di
ng
 se
qu
en
ce
Pa
tie
nt
 ID
Ex
on
/In
tr
on
D
N
A
 V
ar
ia
nt
 M
ut
al
yz
er
Pr
ot
ei
n 
V
ar
ia
nt
 M
ut
al
yz
er
Ty
pe
Lo
ca
te
d
in
 D
N
A
bi
nd
in
g
do
m
ai
n†
Pa
re
nt
al
 o
ri
gi
n
Pr
ed
ic
te
d 
ef
fe
ct
 o
n
pr
ot
ei
n
R
ef
er
en
ce
1
ex
o
n
 1
c.
14
5C
>T
p.
Pr
o4
9S
er
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
2
ex
o
n
 1
c.
89
C>
A
p.
Se
r3
0*
n
o
n
se
n
se
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
3
ex
o
n
 1
c.
87
2_
87
9d
el
8
p.
Se
r2
91
*
n
o
n
se
n
se
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
4
ex
o
n
 1
c.
89
9_
90
3d
up
5
p.
G
ly
30
2C
ys
fs
*7
9
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
5
ex
o
n
 1
c.
19
1C
>A
p.
Se
r6
4*
n
o
n
se
n
se
√
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
6
ex
o
n
 1
c.
69
1_
69
8d
el
8
p.
A
la
23
1A
rg
fs
*6
1
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
7a
ex
o
n
 1
c.
23
5C
>T
p.
G
ln
79
*
n
o
n
se
n
se
√
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
7b
ex
o
n
 2
c.
98
8C
>T
p.
A
rg
33
0T
rp
m
iss
en
se
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
8
ex
o
n
 1
c.
25
6C
>T
p.
A
rg
86
Tr
p
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
9
ex
o
n
 1
c.
30
2C
>T
p.
Se
r1
01
Le
u
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
10
ex
o
n
 1
c.
33
8_
35
8d
el
21
p.
Le
u1
13
_G
ly
11
9d
el
in
fra
m
e 
de
le
tio
n
√
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
11
ex
o
n
 2
c.
11
39
G
>C
p.
*3
80
Se
re
xt
*7
3
n
o
 s
to
p
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
12
ex
o
n
 1
c.
15
8A
>G
p.
Ty
r5
3C
ys
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
13
ex
o
n
 1
c.
93
6d
el
1
p.
Ty
r3
13
Ile
fs
*6
6
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
14
ex
o
n
 1
c.
89
9d
el
1
p.
 L
eu
30
0A
rg
fs
*7
9
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
15
ex
o
n
 1
c.
28
6G
>A
p.
V
al
96
M
et
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
16
ex
o
n
 1
c.
22
1T
>A
pI
le
74
A
sn
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
17
ex
o
n
 1
c.
71
0d
up
C
p.
H
is2
38
A
la
fs
*5
7
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
18
ex
o
n
 1
c.
27
6G
>A
p.
Tr
p9
2*
n
o
n
se
n
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
19
ex
o
n
 2
c.
10
21
_1
02
2i
ns
A
p.
A
rg
34
1G
ln
fs
*7
0
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
20
ex
o
n
 1
c.
15
5C
>T
p.
Se
r5
2P
he
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
21
ex
o
n
 1
c.
27
2_
27
3d
el
in
sA
A
p.
G
ly
91
G
lu
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
22
ex
o
n
 1
c.
84
9_
85
0d
el
2
p.
Ile
28
5G
ln
fs
*9
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
Hum Mutat. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sen et al. Page 15
Pa
tie
nt
 ID
Ex
on
/In
tr
on
D
N
A
 V
ar
ia
nt
 M
ut
al
yz
er
Pr
ot
ei
n 
V
ar
ia
nt
 M
ut
al
yz
er
Ty
pe
Lo
ca
te
d
in
 D
N
A
bi
nd
in
g
do
m
ai
n†
Pa
re
nt
al
 o
ri
gi
n
Pr
ed
ic
te
d 
ef
fe
ct
 o
n
pr
ot
ei
n
R
ef
er
en
ce
23
ex
o
n
 1
c.
53
9C
>A
p.
Se
r1
80
*
n
o
n
se
n
se
de
 n
ov
o
de
le
te
rio
us
Th
is 
St
ud
y
24
ex
o
n
 1
c.
29
0G
>A
p.
A
rg
97
H
is
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
25
ex
o
n
 1
c.
25
4T
>C
p.
Ph
e8
5S
er
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
26
ex
o
n
 1
c.
35
6G
>A
p.
G
ly
11
9A
sp
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
27
ex
o
n
 1
c.
27
2G
>T
p.
G
ly
91
V
al
m
iss
en
se
√
de
 n
ov
o
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
28
ex
o
n
 1
c.
31
0G
>T
p.
G
lu
10
4*
n
o
n
se
n
se
√
n
o
t k
no
w
n
de
le
te
rio
us
Th
is 
stu
dy
29
ex
o
n
 1
c.
81
0G
>A
p.
Tr
p2
70
*
n
o
n
se
n
se
de
 n
ov
o
de
le
te
rio
us
Th
is 
stu
dy
30
ex
o
n
 1
c.
86
2C
>T
p.
G
ln
28
8*
n
o
n
se
n
se
de
 n
ov
o
de
le
te
rio
us
Th
is 
stu
dy
31
ex
o
n
 1
c.
14
6C
>A
p.
Pr
o4
9G
ln
m
iss
en
se
√
n
o
t k
no
w
n
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
32
ex
o
n
 1
c.
37
7C
>T
p.
Pr
o1
26
Le
u
m
iss
en
se
√
n
o
t k
no
w
n
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
33
ex
o
n
 1
c.
31
6T
>C
p.
Ph
e1
06
Le
u
m
iss
en
se
√
n
o
t k
no
w
n
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
34
§
ex
o
n
 1
c.
25
3T
>A
p.
Ph
e8
5I
le
m
iss
en
se
√
lik
el
y 
ge
rm
lin
e 
m
os
ai
ci
sm
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
35
§
ex
o
n
 1
c.
25
3T
>C
p.
Ph
e8
5L
eu
m
iss
en
se
√
m
at
er
na
l
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
stu
dy
36
§
ex
o
n
 1
c.
29
4C
>A
p.
H
is9
8G
ln
m
iss
en
se
√
m
at
er
na
l
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Th
is 
St
ud
y
37
§
ex
o
n
 1
c.
41
6G
>T
p.
A
rg
13
9L
eu
m
iss
en
se
√
m
at
er
na
l
Pr
ob
ab
ly
 d
el
et
er
io
us
¶
Se
n 
et
 a
l 2
01
2
38
ex
o
n
 1
c.
22
5C
>A
p.
Ty
r7
5*
n
o
n
se
n
se
√
de
 n
ov
o
de
le
te
rio
us
St
an
ki
ew
ic
z 
et
al
 
20
09
39
ex
o
n
 1
c.
85
0d
up
T
p.
Ty
r2
84
Le
uf
s*
11
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
St
an
ki
ew
ic
z 
et
al
 
20
09
40
ex
o
n
 2
c.
10
31
_1
03
2d
el
2
p.
Ph
e3
44
Cy
sf
s*
66
fra
m
es
hi
ft
de
 n
ov
o
de
le
te
rio
us
St
an
ki
ew
ic
z 
et
al
 
20
09
41
ex
o
n
 2
c.
11
38
T>
C
p.
*3
80
A
rg
ex
t*
73
n
o
 s
to
p
de
 n
ov
o
de
le
te
rio
us
St
an
ki
ew
ic
z 
et
al
 
20
09
† D
N
A
 b
in
di
ng
 d
om
ai
n 
(M
ah
lap
uu
 et
 a
l 1
99
8)
§ F
am
ili
al
 c
as
e,
 p
re
se
nt
 in
 th
e 
m
ot
he
r
¶ P
re
di
ct
ed
 b
y 
in
 si
lic
o 
pr
ed
ic
tio
n 
pr
og
ra
m
s (
SI
FT
; P
oly
Ph
en
2)
Th
e 
Re
fS
eq
 u
se
d 
w
as
 N
M
_0
01
45
1.
2 
an
d 
th
e m
ut
at
io
ns
 h
av
e b
ee
n 
na
m
ed
 u
sin
g 
di
re
ct
io
ns
 fr
om
 M
ut
al
yz
er
 (h
ttp
s:/
/h
um
ge
np
ro
jec
ts.
lum
c.n
l/tr
ac/
mu
tal
yz
er)
Hum Mutat. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sen et al. Page 16
Ta
bl
e 
2
Cl
in
ic
al
 in
fo
rm
at
io
n 
of
 th
e 
re
po
rte
d 
ca
se
s
pa
tie
nt
 #
G
en
de
r
Et
hn
ic
ity
Bi
rt
h 
w
ei
gh
t (
kg
)
M
ot
he
r’
s a
ge
, p
re
gn
an
cy
G
es
ta
tio
n 
(w
ee
ks
)
A
pg
ar
 1
 &
5 
m
in
D
el
iv
er
y
Li
fe
 sp
an
 (d
ay
s)
D
ia
gn
os
is
M
ed
ic
at
io
ns
EC
M
O
A
ss
oc
ia
te
d 
an
om
al
ie
s
1
M
Ca
uc
as
ia
n
2.
06
28
y,
 G
2P
2
37
 &
 3
/7
8,
 9
V
ag
in
al
29
A
ut
op
sy
Si
ld
en
af
il
N
o
In
co
m
pl
et
e 
ro
ta
tio
n 
of
 b
ow
el
, h
ig
h 
ar
ch
ed
 p
al
at
e,
hy
po
ca
lv
ar
ia
, i
nc
om
pl
et
e 
lu
ng
 lo
ba
tio
n,
 in
co
m
pl
et
e
ro
ta
tio
n 
of
 b
ow
el
2
F
H
isp
an
ic
2.
8
26
y,
 G
3P
2
39
 &
 5
/7
8,
 9
V
ag
in
al
18
A
ut
op
sy
N
itr
ic
 O
xi
de
, M
ilr
in
on
e,
 D
op
am
in
e,
 F
en
ta
ny
l
Y
es
M
al
ro
ta
tio
n 
of
 in
te
sti
ne
, i
m
pe
rfo
ra
te
 a
nu
s, 
bu
tte
rfl
y
v
er
te
br
a
3
M
Ca
uc
as
ia
n
3.
3
22
y,
 G
4P
2
36
9,
 9
V
ag
in
al
35
A
ut
op
sy
N
/A
Y
es
A
or
tic
 c
oa
rc
ta
tio
n,
 M
ec
ke
l’s
 d
iv
er
tic
ul
um
4
F
H
isp
an
ic
3.
6
28
y,
 G
3P
2A
b1
39
9,
 9
El
ec
tiv
e 
c-
se
ct
io
n
16
A
ut
op
sy
N
/A
Y
es
B
ila
te
ra
l i
nc
om
pl
et
e 
lo
ba
tio
n 
of
 lu
ng
s,
ly
m
ph
an
gi
ec
ta
sis
, l
im
ite
d 
au
to
ps
y
5
M
Ca
uc
as
ia
n
3.
0
38
 &
 2
/7
9,
 9
El
ec
tiv
e 
c-
se
ct
io
n
5
A
ut
op
sy
N
itr
ic
 o
xi
de
, M
ilr
in
on
e,
, S
ild
en
af
il,
 E
pi
ne
ph
rin
e,
D
ob
ut
am
in
e,
 N
eu
ro
m
us
cu
la
r b
lo
ck
er
s
Y
es
A
bn
or
m
al
 lu
ng
 lo
ba
tio
n,
 m
al
ro
ta
tio
n 
of
 th
e 
in
te
sti
ne
,
du
od
en
al
 a
tre
sia
6
F
Ca
uc
as
ia
n
3.
2
28
y,
 G
2P
1
39
8,
 9
V
ag
in
al
28
B
io
ps
y
N
itr
ic
 o
xi
de
, M
ilr
in
on
e,
 E
po
pr
os
te
no
l
Y
es
N
o 
au
to
ps
y
7
M
H
isp
an
ic
2.
7
25
y,
 G
1P
0→
1
36
 &
 4
/7
8,
 9
V
ag
in
al
10
B
io
ps
y
N
itr
ic
 o
xi
de
, D
op
am
in
e,
 M
ilr
in
on
e,
 S
ild
en
af
il,
Ep
in
ep
hr
in
e,
 h
yd
ro
co
rti
so
ne
Y
es
N
on
e 
id
en
tif
ie
d
8
F
Ca
uc
as
ia
n
3.
3
28
y,
 G
3P
2
39
6,
 9
V
ag
in
al
12
0
A
ut
op
sy
Si
ld
en
af
il
N
o
B
ilo
be
d 
rig
ht
 lu
ng
9
F
Ca
uc
as
ia
n
4.
02
38
y,
 G
2P
1
38
8,
 9
C-
se
ct
io
n 
fo
r p
ol
yh
yd
ra
m
ni
os
10
A
ut
op
sy
N
itr
ic
 o
xi
de
, m
or
ph
in
e,
 d
op
am
in
e
Y
es
N
on
e 
id
en
tif
ie
d
10
F
A
fri
ca
n 
A
m
er
ic
an
3.
1
25
y,
 G
2P
2
40
 &
 4
/7
8,
 9
V
ag
in
al
14
A
ut
op
sy
N
itr
ic
 o
xi
de
, e
pi
ne
ph
rin
e,
 d
op
am
in
e,
 e
po
pr
os
te
no
l,
Si
ld
en
af
il
Y
es
N
on
e 
id
en
tif
ie
d,
 L
im
ite
d 
au
to
ps
y
11
F
Ca
uc
as
ia
n
3.
7n
al
in
e
38
y,
 G
2P
1→
2
40
8,
 9
V
ag
in
al
95
N
itr
ic
 O
xi
de
, S
ild
en
af
il,
 E
po
pr
os
te
no
l, 
M
ilr
in
on
e,
H
yd
ro
co
rti
so
ne
, M
or
ph
in
e,
Y
es
A
tri
al
 se
pt
al
 d
ef
ec
t
12
F
Ca
uc
as
ia
n
4.
1
N
/A
, G
1P
1
42
N
/A
V
ag
in
al
11
1
B
io
ps
y
N
itr
ic
 O
xi
de
, S
ild
en
af
il
Y
es
N
/A
13
F
Ca
uc
as
ia
n
3.
2
39
y,
 G
1P
1
39
10
, 1
0
V
ag
in
al
42
B
io
ps
y
Si
ld
en
af
il,
 E
po
pr
os
te
no
l, 
M
ilr
in
on
e,
 D
op
am
in
e,
Ep
in
ep
hn
ire
, N
or
ep
in
ep
hr
in
e
Y
es
N
o 
lu
ng
 lo
ba
tio
n
14
M
Ca
uc
as
ia
n
3.
3
26
y,
 G
1p
1
41
 &
 2
/7
9,
 1
0
V
ag
in
al
15
A
ut
op
sy
N
itr
ic
 o
xi
de
, e
po
pr
os
te
no
l, 
su
rfa
ct
an
t a
nd
 c
at
ec
ho
le
am
in
es
N
o
N
on
e 
id
en
tif
ie
d
15
M
Ca
uc
as
ia
n
3.
0
36
y,
 G
2P
1
39
8,
 9
C-
se
ct
io
n 
(h/
o p
rio
r c
-se
cti
on
)
7
B
io
ps
y
N
itr
ic
 o
xi
de
, M
ilr
in
on
e,
 d
op
am
in
e,
 e
po
pr
os
te
no
l
N
o
M
al
ro
ta
tio
n 
of
 th
e 
in
te
sti
ne
, a
tri
al
 se
pt
al
 d
ef
ec
t,
th
ic
ke
ne
d 
di
ste
nd
ed
 b
la
dd
er
 w
ith
 m
us
cu
la
r
hy
pe
rtr
op
hy
16
M
Ca
uc
as
ia
n
2.
1
31
y,
 G
3P
2
32
4,
 8
V
ag
in
al
0.
75
A
ut
op
sy
D
op
am
in
e,
 e
pi
ne
ph
rin
e,
 fe
nt
an
yl
N
o
H
ya
lin
e 
m
em
br
an
e 
di
se
as
e,
 p
at
en
t d
uc
tu
s a
rte
rio
su
s,
m
u
lti
pl
e 
in
te
sti
na
l a
tre
sia
s, 
im
pe
rfo
ra
te
 a
nu
s,
u
n
de
sc
en
de
d 
te
sti
s, 
H
irs
ch
pr
un
g 
di
se
as
e
17
F
Ca
uc
as
ia
n
1.
4
30
y,
 G
1P
1
33
 &
 3
/7
10
, 1
0
V
ag
in
al
7
A
ut
op
sy
Ep
op
ro
ste
no
l
N
o
D
uo
de
na
l a
tre
sia
, p
ol
ys
pl
en
ia
, a
nn
ul
ar
 p
an
cr
ea
s a
nd
le
ft 
hy
dr
on
ep
hr
os
is
18
M
Ca
uc
as
ia
n
2.
8
42
y,
 G
3P
3
38
9,
 1
0
V
ag
in
al
19
B
io
ps
y
N
itr
ic
 O
xi
de
, M
ilr
in
on
e,
 D
op
am
in
e,
 A
m
br
ise
nt
an
Y
es
H
yd
ro
ne
ph
ro
sis
, p
ar
tia
l s
te
no
sis
 a
t t
ra
ns
iti
on
 to
 c
ol
on
tr
an
sv
er
su
m
20
M
Ca
uc
as
ia
n
26
y,
 G
1P
0→
1
40
8,
 8
V
ag
in
al
51
A
ut
op
sy
N
itr
ic
 o
xi
de
, d
op
am
in
e,
 e
pi
ne
ph
rin
e,
 F
en
ta
ny
l,
Y
es
M
al
ro
ta
tio
n 
of
 th
e 
in
te
sti
ne
, h
yd
ro
ne
ph
ro
sis
, b
ila
te
ra
l
hy
dr
ou
re
te
r, 
en
la
rg
ed
 a
nd
 th
ic
k 
bl
ad
de
r
22
M
A
sia
n
3.
3
39
y,
 G
2P
0→
1
38
 &
 2
/7
8,
 9
C-
se
ct
io
n
16
Cl
in
ic
al
ch
ar
ac
te
ris
tic
 a
nd
ge
ne
tic
 m
ut
at
io
n
N
itr
ic
 O
xi
de
, e
pi
ne
ph
rin
e,
 d
op
am
in
e,
 F
en
ta
ny
l, 
M
ilr
in
on
e,
Si
ld
en
af
il
Y
es
N
/A
23
F
Ca
uc
as
ia
n
2.
8
15
y,
 G
1P
1
36
5,
 9
V
ag
in
al
15
A
ut
op
sy
N
itr
ic
 O
xi
de
, d
ob
ut
am
in
e,
 n
or
ep
in
ep
hr
in
e,
 si
ld
en
af
il,
ep
op
ro
ste
no
l
N
o
D
uo
de
na
l s
te
no
sis
, a
nn
ul
ar
 p
an
cr
ea
s, 
m
al
ro
ta
tio
n 
of
la
rg
e 
in
te
sti
ne
Hum Mutat. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sen et al. Page 17
pa
tie
nt
 #
G
en
de
r
Et
hn
ic
ity
Bi
rt
h 
w
ei
gh
t (
kg
)
M
ot
he
r’
s a
ge
, p
re
gn
an
cy
G
es
ta
tio
n 
(w
ee
ks
)
A
pg
ar
 1
 &
5 
m
in
D
el
iv
er
y
Li
fe
 sp
an
 (d
ay
s)
D
ia
gn
os
is
M
ed
ic
at
io
ns
EC
M
O
A
ss
oc
ia
te
d 
an
om
al
ie
s
24
F
Ca
uc
as
ia
n
2.
9
24
y,
 G
1P
0
39
 &
 4
/7
4,
 7
V
ag
in
al
11
B
io
ps
y
D
ob
ut
am
in
e,
 D
op
am
in
e,
 E
pi
ne
ph
rin
e,
 M
ilr
in
on
e
Y
es
M
ec
ke
l’s
 d
iv
ur
tic
ul
um
, m
od
er
at
e 
ac
ut
e 
co
rti
ca
l
in
vo
lu
tio
n 
of
 th
ym
us
25
F
Ca
uc
as
ia
n
2.
7
33
y,
 G
4P
3→
4
37
 &
 5
/7
7,
 9
V
ag
in
al
19
A
ut
op
sy
N
itr
ic
 o
xi
de
, N
or
ad
re
na
lin
, M
ilr
in
on
e,
 D
ob
ut
am
in
e
Y
es
In
te
st
in
al
 m
al
ro
ta
tio
n
26
M
Ca
uc
as
ia
n
3.
5
38
, G
4P
1
39
9,
 9
V
ag
in
al
21
B
io
ps
y
N
itr
ic
 o
xi
de
N
o
M
eg
ad
uo
de
nu
m
, p
yl
or
ic
 st
en
os
is,
 a
nn
ul
ar
 p
an
cr
ea
s
27
F
Ca
uc
as
ia
n
2.
7
34
y,
 G
1P
1
37
 &
 2
/7
8,
 8
V
ag
in
al
16
B
io
ps
y
N
itr
ic
 o
xi
de
, S
ild
en
af
il,
 B
os
en
ta
n
Y
es
N
on
e 
id
en
tif
ie
d
28
M
Ca
uc
as
ia
n
2.
6
34
y,
 G
5P
1
39
9,
 9
C-
se
ct
io
n
19
A
ut
op
sy
N
itr
ic
 o
xi
de
, M
ilr
in
on
e,
 S
ild
en
af
il,
 N
oe
ep
in
ep
hr
in
e
N
o
D
uo
de
na
l a
tre
sia
29
F
Ca
uc
as
ia
n
2.
4
20
y,
 G
1P
1
34
 &
5/
7
8,
 9
V
ag
in
al
12
B
io
ps
y
N
itr
ic
 o
xi
de
, d
op
am
in
e,
 d
ob
ut
am
in
e,
 h
yd
ro
co
rti
so
ne
Y
es
Su
sp
ec
te
d 
jej
un
a a
tre
sia
, n
o a
uto
psy
30
F
Ca
uc
as
ia
n
2.
9
34
y,
 G
1P
0→
1
39
 &
6/
7
7,
 9
V
ag
in
al
15
A
ut
op
sy
D
op
am
in
e,
 d
ob
ut
am
in
e,
 h
yd
ro
co
rti
so
ne
Y
es
Th
ic
ke
ni
ng
 o
f t
he
 p
yl
or
us
31
M
A
sia
n
3.
5
24
, G
1P
1
38
N
/A
V
ag
in
al
N
/A
B
io
ps
y
N
itr
ic
 o
xi
de
, f
ur
os
em
id
e,
 n
ife
di
pi
ne
N
o
Po
st
er
io
r u
re
th
ra
l v
al
ve
s
32
F
A
fri
ca
n 
A
m
er
ic
an
1.
7
37
, G
5P
3→
4
34
8,
 9
V
ag
in
al
N
/A
B
io
ps
y
N
itr
ic
 o
xi
de
, s
ild
en
af
il,
 m
ilr
in
on
e
N
o
A
tri
al
 se
pt
al
 d
ef
ec
ts
33
F
Ca
uc
as
ia
n
3.
2
37
, G
2P
2
37
7,
 9
C-
se
ct
io
n
24
B
io
ps
y
N
itr
ic
 o
xi
de
N
o
B
ut
te
rfl
y 
ve
rte
br
a 
T5
34
.1
M
Ca
uc
as
ia
n
0.
5
29
Te
rm
in
at
ed
 a
t 2
3 
4/
7
N
/A
V
ag
in
al
N
/A
A
ut
op
sy
N
/A
N
o
D
ue
de
na
l a
tre
sia
, m
al
ro
ta
tio
n 
of
 th
e 
la
rg
e 
in
te
sti
ne
,
an
al
 a
tre
sia
, g
al
lb
la
dd
er
 a
ge
ne
sis
34
.2
M
Ca
uc
as
ia
n
2.
6
30
39
 3
/7
N
/A
V
ag
in
al
17
A
ut
op
sy
N
itr
ic
 o
xi
de
, s
ild
en
af
il,
 b
os
en
ta
n,
 d
ob
ut
am
in
e,
 a
dr
en
al
in
e,
n
o
ra
dr
en
al
in
e
Y
es
N
on
e 
de
te
ct
ed
35
F
Ca
uc
as
ia
n
2.
8
30
y,
 G
3 
P1
38
 &
 5
/7
3,
 9
El
ec
tiv
e 
C-
se
ct
io
n
50
Cl
in
ic
al
ch
ar
ac
te
ris
tic
 a
nd
ge
ne
tic
 m
ut
at
io
n
D
ob
ut
am
in
e,
 M
ilr
in
on
e,
 B
os
en
ta
n,
 S
ild
en
af
il
N
o
A
tri
al
 se
pt
al
 d
ef
ec
t, 
po
ly
hy
dr
am
ni
os
36
M
A
sia
n/
Ca
uc
as
ia
n
3.
0
31
y,
 G
3P
3
37
 &
 5
/7
7,
 8
C-
se
ct
io
n 
(br
ee
ch
 pr
ese
nta
tio
n)
2
A
ut
op
sy
D
ob
ut
am
in
e,
 d
op
am
in
e,
 a
dr
en
al
in
e,
 n
oe
ep
in
ep
hr
in
e
N
o
A
tri
al
 se
pt
al
 d
ef
ec
t, 
po
ly
hy
dr
am
ni
os
37
.1
F
Ca
uc
as
ia
n
3.
4
25
y,
 G
2P
1
39
9,
 9
V
ag
in
al
17
A
ut
op
sy
N
itr
ic
 o
xi
de
, d
op
am
in
e,
 d
ob
ut
am
in
e,
 to
la
zo
lin
N
o
N
/A
37
.2
M
Ca
uc
as
ia
n
N
/A
25
y
Te
rm
in
at
ed
 a
t 2
1 
w
ee
ks
N
/A
V
ag
in
al
N
/A
A
ut
op
sy
N
/A
N
o
U
re
tra
l s
te
no
sis
, h
yd
ro
ne
ph
ro
sis
,
37
.3
M
Ca
uc
as
ia
n
3.
2
27
y,
 G
4P
2
37
 &
 1
/7
9,
 1
0
V
ag
in
al
0.
16
6
A
ut
op
sy
Su
rfa
ct
an
ts 
&
 C
at
ec
ho
la
m
in
es
N
o
Pu
lm
on
ar
y 
hy
po
pl
as
ia
, h
yd
ro
th
or
ax
, p
ol
yh
yd
ra
m
ni
os
37
.4
F
Ca
uc
as
ia
n
3.
2
31
y,
 G
5P
3
39
9,
 9
V
ag
in
al
1
A
ut
op
sy
N
itr
ic
 o
xi
de
, C
at
ec
ho
la
m
in
es
N
o
Is
ol
at
ed
 a
rh
in
en
ce
ph
al
y
37
.5
M
Ca
uc
as
ia
n
N
/A
36
y
Te
rm
in
at
ed
 a
t 2
2 
w
ee
ks
N
/A
V
ag
in
al
N
/A
A
ut
op
sy
N
/A
N
o
O
bs
tru
ct
iv
e 
ur
op
at
hy
N
/A
 N
ot
 a
va
ila
bl
e.
 C
lin
ic
al
 in
fo
rm
at
io
n 
of
 c
as
es
 1
9 
an
d 
21
 ar
e n
ot
 av
ai
la
bl
e. 
Th
e c
lin
ic
al
 in
fo
rm
at
io
n 
of
 ca
se
s 3
8 
– 
41
 h
av
e b
ee
n 
pr
es
en
te
d 
in
 S
ta
nk
ie
w
ic
z e
t a
l 2
00
9.
Hum Mutat. Author manuscript; available in PMC 2014 June 01.
